Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Updated survival results of the randomized, phase III DESTINY-Breast04 study

被引：16
作者：
Modi, S. [1 ]
Jacot, W. [2 ]
Iwata, H. [3 ]
Park, Y. H. [4 ]
Vidal Losada, M. J. [5 ]
Li, W. [6 ]
Tsurutani, J. [7 ]
Zaman, K. [8 ]
Ueno, N. T. [9 ]
Prat, A. [10 ]
Papazisis, K. [11 ]
Rugo, H. S. [12 ]
Harbeck, N. [13 ]
Im, S-A. [14 ]
De Laurentiis, M. [15 ]
Orbegoso, C. M. A. [16 ]
Yung, L. [17 ]
Cheng, F-C. [18 ]
Cheng, Y. [19 ]
Cameron, D. A. [20 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[2] Inst Canc Montpellier, Med Oncol, Montpellier, France
[3] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan
[4] Samsung Med Ctr, Hematol Oncol, Seoul, South Korea
[5] Hosp Clin Barcelona, Oncol Med, Barcelona, Spain
[6] First Hosp Jilin Univ, Tumor Ctr, Changchun, Jilin, Peoples R China
[7] Showa Univ, Adv Canc Translat Res Inst, Shinagawa, Japan
[8] Lausanne Univ Hosp CHUV, Oncol, Lausanne, Switzerland
[9] Univ Hawaii, Med, Ctr Canc, Honolulu, HI USA
[10] August Pi & Sunyer Biomed Res Inst IDIBAPS, Med Oncol, Translat Genom & Targeted Therapies Grp, Barcelona, Spain
[11] Euromed Gen Clin, Oncol, Thessaloniki, Greece
[12] UCSF, Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[13] LMU Univ Hosp, Breast Ctr, Obstet & Gynecol, Munich, Germany
[14] Seoul Natl Univ, Seoul Natl Univ Hosp, Internal Med, Coll Med, Seoul, South Korea
[15] Ist Nazl Tumori IRCCS Fdn G Pascale, Breast Oncol Unit, Naples, Italy
[16] Daiichi Sankyo Inc, Global Oncol Res & Dev, Rueil Malmaison, France
[17] Daiichi Sankyo Inc, Global Oncol R&D, Basking Ridge, NJ USA
[18] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA
[19] Daiichi Sankyo Inc, Clin Safety & Pharmacovigilance, Basking Ridge, NJ USA
[20] Univ Edinburgh, Edinburgh Univ Canc Ctr, Edinburgh, Midlothian, Scotland
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
376O
引用
收藏
页码：S334 / S335
页数：2
相关论文
共 50 条
  • [41] Multicenter Retrospective Cohort Study of the Sequential Use of the Antibody-Drug Conjugates (ADCs) Trastuzumab Deruxtecan (T-DXd) and Sacituzumab Govitecan (SG) in Patients With HER2-Low Metastatic Breast Cancer (MBC)
    Bardia, Aditya
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [42] Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
    Laura A. Huppert
    Reshma Mahtani
    Samantha Fisch
    Naomi Dempsey
    Sarah Premji
    Angelina Raimonde
    Saya Jacob
    Laura Quintal
    Michelle Melisko
    Jo Chien
    Ana Sandoval
    Lauren Carcas
    Manmeet Ahluwalia
    Natasha Harpalani
    Jenna Hoppenworth
    Anne Blaes
    Kelly Blum
    Mi-Ok Kim
    Dame Idossa
    Ruta Rao
    Karthik V. Giridhar
    Hope S. Rugo
    npj Breast Cancer, 11 (1)
  • [43] Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
    Huppert, Laura
    Mahtani, Reshma
    Fisch, Samantha
    Dempsey, Naomi
    Premji, Sarah
    Raimonde-Taylor, Angelina
    Jacob, Saya
    Quintal, Laura
    Chien, Jo
    Melisko, Michelle
    Sandoval-Leon, Ana
    Carcas, Lauren
    Ahluwalia, Manmeet
    Harpalani, Natasha
    Hoppenworth, Jenna
    Idossa, Dame
    Rao, Ruta
    Giridhar, Karthik
    Rugo, Hope
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Rescue Therapy with Trastuzumab Deruxtecan (T-Dxd) in Patients with primary hepatic metastatic Her2 low Breast Cancer with marked Hyperbilirubinemia
    Wolf, M.
    Sili, F.
    Sulejmani, V.
    Schuepferling, A.
    Bomhard, J.
    Huber, M.
    Sigl, S.
    Schnelzer, A.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (06) : E44 - E44
  • [45] Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)
    Curigliano, Giuseppe
    Hu, Xichun
    Dent, Rebecca Alexandra
    Yonemori, Kan
    Barrios Sr, Carlos H.
    O'Shaughnessy, Joyce
    Wildiers, Hans
    Zhang, Qingyuan
    Im, Seock-Ah
    Saura, Cristina
    Biganzoli, Laura
    Sohn, Joohyuk
    Levy, Christelle
    Jacot, William
    Begbie, Natasha
    Ke, Jun
    Patel, Gargi Surendra
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA1000 - LBA1000
  • [46] Updated results of a randomized phase III study of trastuzumab, paclitaxel and carboplatin versus trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC): efficacy and safety
    Robert, Nicholas
    Leyland-Jones, Brian
    Asmar, Lina
    Belt, Robert
    Ilegbodu, Des
    Loesch, David
    Raju, Robert
    Cobleigh, Melody
    Albain, Kathy
    Slamon, Dennis
    ANNALS OF ONCOLOGY, 2004, 15 : 39 - 39
  • [47] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC)
    Kumar, Prashanth Ashok
    Sandhu, Michael
    Sravanthi, Metlapalli Venkata
    Kumar, Vishnu Charan Suresh
    Benjamin, Sam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study.
    Raghav, Kanwal Pratap Singh
    Siena, Salvatore
    Takashima, Atsuo
    Kato, Takeshi
    Van den Eynde, Marc
    Di Bartolomeo, Maria
    Komatsu, Yoshito
    Kawakami, Hisato
    Peeters, Marc
    Andre, Thierry
    Lonardi, Sara
    Yamaguchi, Kensei
    Tie, Jeanne
    Castro, Cristina Gravalos
    Strickler, John H.
    Barrios, Daniel
    Yan, Qi
    Kamio, Takahiro
    Kobayashi, Kojiro
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice of treatment in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 trial (DESTINY-Breast02)
    Andre, Fabrice
    Shahidi, Javad
    Lee, Caleb
    Wang, Kongming
    Krop, Ian E.
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 Study
    Krop, I.
    Saura Manich, C.
    Yamashita, T.
    Park, Y. H.
    Kim, S. -B. K.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Denduluri, N.
    Perrin, C.
    Aogi, K.
    Tokunaga, E.
    Im, S. -A.
    Lee, K. S.
    Hurvitz, S.
    Cortes, J.
    Lee, C.
    Chen, S.
    Zhang, L.
    Shahidi, J.
    Yver, A.
    Modi, S.
    SWISS MEDICAL WEEKLY, 2020, : 25S - 25S
12345